Q32 Bio Inc.
No enriched coverage for $QTTB in the last 7 days.
No SEC Form 4 filings for $QTTB in the last 30 days.
See all $QTTB insider activity →Oppenheimer reiterated an Outperform rating and $40.00 price target for Q32 Bio (QTTB) after positive trial data for bempikibart in alopecia areata. The stock fell 13.2% on September 30, but remains up 149% year-to-date. Multiple analysts have raised price targets or initiated coverage with positive ratings, citing the drug's potential.
Q32 Bio Inc. (QTTB) stock fell 1.4% in pre-market trading, continuing volatility after its Phase 2a data presentation. Analysts remain bullish, with Oppenheimer and Jefferies maintaining positive outlooks. The broader market showed modest gains, supported by softer inflation data. The stock's decline is attributed to post-catalyst digestion rather than new negative developments.
Q32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.
Recent QTTB coverage spans financial news, market movers and technology.
Analyst upgrade based on new trial data suggests upside potential.
Continued selling pressure as market digests Phase 2a readout.
Positive Phase 2a data and analyst initiations drive strong buying pressure.
Positive trial data likely lifts QTTB as investors anticipate progression to registration trials.
Executive hires and encouraging trial data may boost investor confidence and support a price uptick.
AlphAI scores every news story that mentions QTTB with an AI model for sentiment and relevance, and aggregates insider trades from Q32 Bio Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Oppenheimer reiterated an Outperform rating and $40.00 price target for Q32 Bio (QTTB) after positive trial data for bempikibart in alopecia areata. The stock fell 13.2% on September 30, but remains up 149% year-to-date. Multiple analysts have raised price targets or initiated coverage with positive ratings, citing the drug's potential.
2 min readQ32 Bio Inc. (QTTB) stock fell 1.4% in pre-market trading, continuing volatility after its Phase 2a data presentation. Analysts remain bullish, with Oppenheimer and Jefferies maintaining positive outlooks. The broader market showed modest gains, supported by softer inflation data. The stock's decline is attributed to post-catalyst digestion rather than new negative developments.
1 min readQ32 Bio (QTTB) stock surged 20.8% in pre-market trading after releasing Phase 2a results for bempikibart at the EADV Congress. The data showed 36-week efficacy and 16-week off-drug findings for alopecia areata. Analysts initiated coverage with Buy ratings and price targets of $29 (Jefferies) and $38 (Clear Street), citing high revenue potential and favorable safety profile. The broader market had a mild positive impact.
2 min readQ32 Bio (QTTB) presented 36-week results from its SIGNAL-AA Phase 2a trial of bempikibart for alopecia areata at EADV 2026. The drug showed clinically meaningful efficacy, with a 35.3% mean reduction in SALT scores. 40% of patients achieved SALT-20 response. The 16-week off-drug period showed durable responses, with 44% maintaining SALT-20. Q32 Bio plans to advance a registration-directed program in 2027.
2 min readQ32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.
2 min readQ32 Bio Inc. (QTTB) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer — Dr. Trevejo is a physician-scientist and biotechnology executive with over 20 years of experience spanning dermatology and late-stage
2 min readApple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.
2 min readMorrison Jodie Pope (CEO) sold 9,845 shares of Q32 Bio Inc. (FIXX) at $16.56 ($0.16M total) on 2026-08-25.
1 min readAnalysts made several ratings changes: UBS upgraded Celestica to Buy with a $430 target, citing AI-driven demand. Citi initiated Reformation as Buy with a $20 target. Morgan Stanley initiated Jersey Mike's and ArcelorMittal as Overweight. Baird upgraded Darden to Outperform and downgraded Chipotle to Neutral. Other notable moves include upgrades for Suzano, Ionic Digital, and Fortune Brands, while Canada Goose was downgraded.
2 min readQ32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented
6 min read
